ClinicalTrials.gg
RecruitingNCT07367282nAMDUpdated Jul 27, 2026

Evaluate the Efficacy of Faricimab in Patients With Neovascular Age-related Macular Degeneration

A Phase 4 interventional study of Faricimab Injection [Vabysmo] in Macular Degeneration, sponsored by Junyeop Lee. Recruiting at 5 sites in South Korea. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by Junyeop Lee · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
64
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies testing faricimab in Macular Degeneration — 6 open to participants now, 7 under way, 2 of them phase 3. faricimab · Macular Degeneration.

Planned enrollment
7th of 14
64 · median 57
Started
2026
with 2 others
Phase 4
5 of 14
3 open now
Registered
12th of 14
by date
Lead sponsor
1 of 14
Junyeop Lee

Among the 14 studies testing faricimab in Macular Degeneration, this one is the 7th largest by planned enrollment, is one of 3 that started in 2026, is one of 5 in phase 4, and was the 12th registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

6 of the 14 studies testing faricimab in Macular Degeneration are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About faricimab

faricimab: first FDA approval 2022 (VABYSMO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing faricimab in Macular Degeneration, or all of them as a file.
02

Study summary

If the subject who has nAMD voluntarily agrees to participate in this clinical study by signing the informed consent form, screening assessments will be conducted within 4 weeks prior to the first dose of the investigational drug. During the screening visit, the eligibility of the subject will be assessed and one study eye will be selected. If both eyes are eligible, the eye with the worst best-corrected visual acuity (BCVA) at screening will be chosen. However, if the investigator determines that the other eye requires more urgent treatment for clinical reasons, that eye may be selected as the study eye.

After screening assessments and evaluation based on inclusion/exclusion criteria, eligible subjects will be enrolled. Vabysmo® 6 mg (0.05 mL) will be administered via intravitreal injection every 4 weeks (monthly) for a total of 4 doses during the initial loading period. After the loading dose, patients will undergo disease activity assessment based on imaging and visual acuity (VA) outcomes followed by the IP administration at Week 20. The treatment interval will be determined based on disease activity assessed at Week 20, depending on the results, the subsequent administration may be scheduled at Week 28 or Week 32, at the investigator's discretion. Thereafter, the dosing interval may be further adjusted in 4-week increments, either extended or shortened, according to imaging and visual outcomes.

Throughout the clinical study, patients will need to visit the study site at least 10 times, including the screening visit. The number of intravitreal injections administered will be 4 doses during the initial loading period and up to 5 doses during the treat-and-extend (T\&E) period (Weeks 20, 28, 36, 44, 52). Thus, the total number of injections during the study will range from a minimum of 7 to a maximum of 9 injections.

If the non-study eye also has nAMD, treatment with a locally approved therapy may be administered outside the scope of this study.

03

Conditions studied

  • Macular Degeneration

Keywords

  • Neovascular Age-related Macular Degeneration
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Individuals who voluntarily agree to participate in this clinical study and provide written
  2. Male or female adults aged 50 years or older at the time of consent
  3. Individuals who, in the opinion of the investigator, are capable of complying with the requirements of the study protocol

Ocular Conditions

  1. Individuals with a BCVA equivalent of ETDRS 24 letters or more, as measured at the time of screening.
  2. Confirmed diagnosis, by the investigator, of active nAMD based on sufficiently clear ocular media and adequate pupillary dilation allowing acquisition of good quality retinal images for confirmation.
  3. Treatment naïve patients
  4. For PCV patients, presence of active polypoidal lesions in the macula as shown by Indocyanine green angiography (ICGA) AND presence of serosanguinous maculopathy
  5. For PCV patients, greatest liner dimension (GLD) of the total lesion area \<5400 μm as delineated by ICGA.

Exclusion criteria

Exclusion Criteria:

  1. Any major illness or major surgical procedure within 1 month before screening.
  2. Any condition that, in the opinion of the investigator, constitutes a to the use of faricimab, may affect interpretation of study results, or places the participant at high risk for treatment-related complications, based on medical history, non-diabetic metabolic abnormalities, physical examination findings, or past/current clinical laboratory results.
  3. History of active cancer within 12 months prior to screening, except for adequately treated carcinoma in situ of the cervix, non-melanoma skin cancer, or prostate cancer with a Gleason score ≤6 (Grade Group 1) and stable PSA levels for >12 months.
  4. Uncontrolled blood pressure, defined as systolic >180 mmHg and/or diastolic >100 mmHg while at rest at baseline. A repeat reading within the screening window may be taken to confirm eligibility.
  5. Immune system abnormalities that may affect inflammatory biomarkers in aqueous humor (AH).
  6. History of severe allergic or anaphylactic reaction to biologic agents, or known to any component of the faricimab injection, study-related procedures (including fluorescein and indocyanine green dyes), dilating drops, or any anesthetic/antimicrobial eye drops used during the study.
  7. Systemic treatment for suspected or active systemic infection at screening. Ongoing prophylactic antibiotic use may be acceptable at the investigator's discretion.
  8. Use of systemic medications known to have toxic effects on the lens, retina, or optic nerve within 6 months prior to screening or within 5 drug half-lives (whichever is longer), or expected future use of such medications.
  9. Receipt of systemic immunomodulatory therapy or agents within 6 months prior to screening or within 5 drug half-lives (whichever is longer).
  10. Participation in another clinical study involving an drug, investigational device, or other medical research within 3 months prior to screening, or concurrent participation in such a study.
  11. Pregnant or breastfeeding women.
  12. Women of planning to become pregnant during the study or within 3 months after the last dose of study treatment, or unwilling to use highly effective methods* throughout the study period and for 3 months following the last dose.

Ocular Conditions

  1. Any ocular condition in the study eye that may interfere with the assessment of visual acuity, safety evaluation, or fundus imaging (e.g., advanced cataract).
  2. Any current ocular disease in the study eye that, in the opinion of the investigator, increases the procedural risk of intravitreal injection beyond standard expectations or may interfere with injection, efficacy, or safety evaluations.
  3. Presence of fibrosis or atrophy involving ≥50% of the total lesion area and/or the fovea in the study eye, as determined by the investigator.
  4. Presence of retinal pigment epithelial (RPE) tear involving the macula in the study eye.
  5. High myopia with spherical equivalent refractive error >6 diopters in the study eye. For participants with a history of refractive or cataract surgery, pre-surgical refractive error must not have exceeded -6 diopters.
  6. Presence of vitreous hemorrhage in the study eye at screening or baseline visits.
  7. History of other macular diseases in the study eye that are unrelated to nAMD but may lead to visual loss or cause intraretinal fluid (IRF) or subretinal fluid (SRF).
  8. History or clinical evidence of proliferative diabetic retinopathy, diabetic macular edema, or other retinal vascular diseases in the study eye, other than AMD.
  9. Any current ocular condition in the study eye (e.g., cataract) that, in the opinion of the investigator, may require medical or surgical intervention during the study period.
  10. History of prior intraocular surgery in the study eye, including but not limited to vitrectomy, glaucoma surgery, corneal transplant, radiation therapy, retinal detachment repair (e.g., scleral buckle or pneumatic retinopexy), trabeculectomy, or other filtration surgeries.
  11. History of prior or ongoing treatment for macular neovascularization (MNV) or vitreomacular interface abnormalities in the study eye, including but not limited to intravitreal therapy (faricimab, other anti-VEGF agents, , tissue plasminogen activator, ocriplasmin, C3F8 gas, air), periocular pharmacological interventions, argon laser photocoagulation, verteporfin photodynamic therapy, diode laser, transpupillary thermotherapy, or ocular surgical procedures.
  12. Presence of glaucoma in the study eye with uncontrolled intraocular pressure ≥25 mmHg despite pharmacological therapy.
  13. Presence of active ocular inflammation or suspected or active ocular or periocular infection in either eye at screening.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Faricimab

    Faricimab injection

    Drug: Faricimab Injection [Vabysmo]

Interventions

06

What researchers measure

Primary outcomes

  1. ANG-2 level in aqueous humour (AH)

    Measurement of ANG-2 levels in aqueous humor (AH) and the change from baseline to week 20

    Time frame: at Week 20 from baseline

Secondary outcomes

  1. Endothelial ANG-2 level in aqueous humour (AH)

    Changes of endothelial ANG-2 level in aqueous humour (AH) at visits compared from baseline at Weeks 4, 12, 20 and 52

    Time frame: At weeks 4, 12, 20 and 52 from baseline

  2. BCVA measurement

    Best Corrected Visual Acuity (BCVA) change from baseline at Weeks 20 and 52

    Time frame: At weeks 20 and 52 from baseline

  3. Subfoveal choroidal thickness

    Change in subfoveal choroidal thickness at Weeks 20 and 52 compared to baseline (limited to PCV patients)

    Time frame: At weeks 20 and 52 from baseline

  4. Central subfield thickness (CST)

    Central subfield thickness (CST) change from baseline at Weeks 20 and 52

    Time frame: At weeks 20 and 52 from baseline

  5. Intraretinal microaneurysms and vessel density of the deep capillary plexus

    Change in the number of intraretinal microaneurysms and vessel density of the deep capillary plexus at Weeks 20 and 52 compared to baseline

    Time frame: At weeks 20 and 52 from baseline

  6. Area of peripheral non-perfusion in the retina

    Change in the area of peripheral non-perfusion in the retina at Weeks 20 and 52 compared to baseline

    Time frame: At weeks 20 and 52 from baseline

  7. High improvement in vascular stabilization

    Proportion of patients who achieved high improvement in vascular stabilization at Week 20 (defined as 2 or more score in Macular Neovascularization Stabilisation Scoring System Score range 0-4, higher scores mean a better outcome)

    Time frame: from baseline at Weeks 20

  8. Complete polyp regression

    Proportion of subjects who experienced complete polyp regression at least once by Weeks 20 and 52 compared to baseline (limited to PCV patients)

    Time frame: At weeks 20 and 52 from baseline

  9. Polyp inactivation

    Proportion of subjects who experienced polyp inactivation at least once by Weeks 20 and 52 compared to baseline (limited to PCV patients)

    Time frame: At weeks 20 and 52 from baseline

  10. Resolution of central Intraretinal fluid/Subretinal fluid(IRF/SRF)

    Proportion of subjects with resolution of central IRF/SRF at Weeks 20 and 52 compared to baseline

    Time frame: At weeks 20 and 52 from baseline

  11. Vascular remodeling

    Proportion of subjects who experiences vascular remodeling with changes in choroidal angiographic features at Weeks 20 and 52 compared to baseline

    Time frame: At weeks 20 and 52 from baseline

  12. Number of injections per patient

    Mean number of injections per patient

    Time frame: From baseline to Week 52(EOS)

  13. Treatment interval

    Proportion of subjects who achieved a treatment interval of ≥12 or 16 weeks at least once during the Treat \& Extend period

    Time frame: From baseline to Week 52(EOS)

  14. Maximum treatment interval

    Distribution of maximum treatment interval during the Treat \& Extend period

    Time frame: From baseline to Week 52(EOS)

Other outcomes

  1. AH biomarkers and imaging biomarkers

    Correlation between AH biomarkers and imaging biomarkers

    Time frame: From baseline to Week 52(EOS)

  2. AH biomarkers and the maximum treatment interval

    Correlation between AH biomarkers and the maximum treatment interval achieved during the T\&E period

    Time frame: From baseline to Week 52(EOS)

07

Study locations

3 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Apr 2028, 22 months after the start.

Of 45 phase 4 interventional studies under Macular Degeneration, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 39. This study's planned 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2026
First posted
Jan 26, 2026
StartActual
Jun 29, 2026
Primary completionEst.
Apr 30, 2028
CompletionEst.
Dec 31, 2028
Last update
Jul 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07367282
Lead sponsor
Junyeop Lee
Responsible party
Junyeop Lee (Professor, Asan Medical Center) — Sponsor-investigator
First posted
Jan 26, 2026
Start date
Jun 29, 2026
Primary completion
Apr 30, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jul 27, 2026

Study contacts

Junyeop Lee, PhD
Contact
j.lee.amc@gmail.com
82-2-3010-3975
Junyeop Lee, PhD
study director · Asan Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Faricimab

Start the discussion